...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Virology >On‐treatment changes of serum Wisteria floribunda Wisteria floribunda agglutinin‐positive Mac‐2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add‐on therapy
【24h】

On‐treatment changes of serum Wisteria floribunda Wisteria floribunda agglutinin‐positive Mac‐2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add‐on therapy

机译：血清紫藤的治疗变化Floribunda Wisteria Floribunda alglutinin阳性Mac-2结合蛋白与肝纤维化的回归有关的慢性乙型肝炎患者在干扰素α附加治疗中的肝纤维化

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein (M2BP) has been identified as a predictor for the response of interferon α (IFN‐α) in patients with viral hepatitis. However, whether serum glycosylation isomer of M2BP (M2BPGi) was associated with the regression of liver fibrosis in patients with chronic hepatitis B (CHB) during IFN‐α add‐on therapy is still unknown. CHB patients were treated with entecavir for 26 weeks followed by entecavir plus pegylated IFN‐α for 52 weeks. Liver biopsies were taken at baseline and treatment week 78. The regression of fibrosis was identified according to Ishak standard or Ishak plus Progressive‐Indeterminate‐Regressive (P‐I‐R) standard. Serum M2BPGi and liver function tests were measured at baseline and every 26 weeks of treatment. A total of 72 CHB patients were included in the present study. Serum M2BPGi was correlated with fibrosis and necroinflammation both at baseline and week 78. If Ishak standard was used as the reference, only the percent change of M2BPGi at week 52 from week 26 (Δ%M2BPGi 26w‐52W ) was independently associated with fibrosis regression at treatment week 78, the area under the ROC curve (AUROC) of Δ%M2BPGi 26w‐52W for predicting fibrosis regression was 0.705. As for Ishak plus P‐I‐R standard, the AUROC of the predictive model for fibrosis regression (0.896*M2BPGi 52W ?+?0.363*necroinflammation score 0w ?+?2.051*Ishak score 0w ?–?4.489) was 0.888. These data indicated that dynamic changes of serum M2BPGi were associated with fibrosis regression in CHB patients on IFN‐α add‐on therapy.
机译：摘要Wisteria Floribunda氨基丙氨酸阳性MAC-2结合蛋白（M2BP）已被鉴定为病毒性肝炎患者干扰素α（IFN-α）的响应的预测因子。然而，M2BP（M2BPGI）的血清糖基化异构体是否与IFN-α加载疗法期间慢性乙型肝炎（CHB）患者的肝纤维化的回归相关。将CHB患者用Entecavir治疗26周，然后用恩替替卡韦加聚乙二醇化IFN-α52周。肝脏活组织检查是在基线和治疗周78中拍摄的。根据Ishak标准或Ishak加上渐进式 - 退回（P-I-R）标准鉴定了纤维化的回归。在基线和每26周的治疗中测量血清M2BPGI和肝功能试验。本研究共纳入72例CHB患者。血清M2BPGI在基线和第78周中与纤维化和NeCroin炎症相关。如果使用ISHAK标准作为参考，则仅在第26周（Δ％M2BPGI 26W-52W）的第52周仅为M2BPGI的百分比与纤维化回归独立相关在治疗周78中，ROC曲线（Auroc）下的面积为δ％M2BPGI 26W-52W，用于预测纤维化回归为0.705。至于ISHAK PLUS P-I-R标准，纤维化回归预测模型的氧化氢氧化物（0.896 * M2BPGI 52W？+ 0.363 * NeCroinflation得分0W？+？2.051 * ISHAK得分0W？ - ？4.489）为0.888。这些数据表明，血清M2BPGI的动态变化与IFN-α附加治疗中CHB患者的纤维化回归相关。

著录项

  • 来源
    《Journal of Medical Virology》 |2019年第8期|共11页
  • 作者

    Liu Tianhui; Sun Yameng; Zhou Jialing; Yang Fang; Zou Xia; Wang Lin; Wu Xiaoning; Chen Yongpeng; Piao Hongxin; Lu Lungen; Jiang Wei; Xu Youqing; Feng Bo; Nan Yuemin; Xie Wen; Chen Guofeng; Zheng Huanwei; Li Hai; Ding Huiguo; Liu Hui; Wang Tailing; Ou Xiaojuan; Wu Shanshan; Kong Yuanyuan; Wang Ping; Cong Min; Zhang Yan; You Hong; Jia Jidong;

  • 作者单位

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Key Laboratory of Systems Biomedicine Ministry of Education Shanghai Center for Systems;

    Key Laboratory of Systems Biomedicine Ministry of Education Shanghai Center for Systems;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Department of Infectious DiseasesNanfang Hospital Southern Medical UniversityGuangzhou Guangdong;

    Department of?Infectious?DiseasesAffiliated Hospital of Yanbian UniversityYanji China;

    Department of Gastroenterology and HepatologyShanghai General Hospital Shanghai Jiao Tong;

    Department of GastroenterologyZhongshan Hospital Fudan UniversityShanghai China;

    Department of Digestive SystemBeijing Tiantan Hospital Capital Medical UniversityBeijing China;

    Hepatology InstitutePeking University People's HospitalBeijing China;

    Department of Traditional and Western Medical HepatologyThird Hospital of Hebei Medical University;

    Center of Liver DiseasesBeijing Ditan Hospital Capital Medical UniversityBeijing China;

    Second Liver Cirrhosis Diagnosis and Treatment CenterMilitary Hospital of ChinaBeijing China;

    Department of Infectious DiseaseThe Fifth Hospital of Shijiazhuang CityShijiazhuang China;

    Department of Hepatopancreatobiliary and Splenic MedicineAffiliated Hospital Logistics University;

    Department of Gastroenterology and HepatologyBeijing Youan Hospital Capital Medical;

    Department of PathologyBeijing Youan Hospital Capital Medical UniversityBeijing China;

    Department of PathologyChina‐Japan Friendship HospitalBeijing China;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Clinical Epidemiology and Evidence‐Based Medicine UnitNational Clinical Research Center for;

    Clinical Epidemiology and Evidence‐Based Medicine UnitNational Clinical Research Center for;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Key Laboratory of Systems Biomedicine Ministry of Education Shanghai Center for Systems;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

    Liver Research CenterBeijing Friendship Hospital Capital Medical University Beijing Key;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学微生物学（病原细菌学、病原微生物学）;
  • 关键词

    chronic hepatitis B; interferon α; liver fibrosis; M2BPGi; regression;

    机译：慢性乙型肝炎;干扰素α;肝纤维化;m2bpgi;回归;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号